Cargando…

Targeting epigenetic regulators to overcome drug resistance in cancers

Drug resistance is mainly responsible for cancer recurrence and poor prognosis. Epigenetic regulation is a heritable change in gene expressions independent of nucleotide sequence changes. As the common epigenetic regulation mechanisms, DNA methylation, histone modification, and non-coding RNA regula...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Nan, Ma, Ting, Yu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935618/
https://www.ncbi.nlm.nih.gov/pubmed/36797239
http://dx.doi.org/10.1038/s41392-023-01341-7
_version_ 1784890055110688768
author Wang, Nan
Ma, Ting
Yu, Bin
author_facet Wang, Nan
Ma, Ting
Yu, Bin
author_sort Wang, Nan
collection PubMed
description Drug resistance is mainly responsible for cancer recurrence and poor prognosis. Epigenetic regulation is a heritable change in gene expressions independent of nucleotide sequence changes. As the common epigenetic regulation mechanisms, DNA methylation, histone modification, and non-coding RNA regulation have been well studied. Increasing evidence has shown that aberrant epigenetic regulations contribute to tumor resistance. Therefore, targeting epigenetic regulators represents an effective strategy to reverse drug resistance. In this review, we mainly summarize the roles of epigenetic regulation in tumor resistance. In addition, as the essential factors for epigenetic modifications, histone demethylases mediate the histone or genomic DNA modifications. Herein, we comprehensively describe the functions of the histone demethylase family including the lysine-specific demethylase family, the Jumonji C-domain-containing demethylase family, and the histone arginine demethylase family, and fully discuss their regulatory mechanisms related to cancer drug resistance. In addition, therapeutic strategies, including small-molecule inhibitors and small interfering RNA targeting histone demethylases to overcome drug resistance, are also described.
format Online
Article
Text
id pubmed-9935618
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-99356182023-02-18 Targeting epigenetic regulators to overcome drug resistance in cancers Wang, Nan Ma, Ting Yu, Bin Signal Transduct Target Ther Review Article Drug resistance is mainly responsible for cancer recurrence and poor prognosis. Epigenetic regulation is a heritable change in gene expressions independent of nucleotide sequence changes. As the common epigenetic regulation mechanisms, DNA methylation, histone modification, and non-coding RNA regulation have been well studied. Increasing evidence has shown that aberrant epigenetic regulations contribute to tumor resistance. Therefore, targeting epigenetic regulators represents an effective strategy to reverse drug resistance. In this review, we mainly summarize the roles of epigenetic regulation in tumor resistance. In addition, as the essential factors for epigenetic modifications, histone demethylases mediate the histone or genomic DNA modifications. Herein, we comprehensively describe the functions of the histone demethylase family including the lysine-specific demethylase family, the Jumonji C-domain-containing demethylase family, and the histone arginine demethylase family, and fully discuss their regulatory mechanisms related to cancer drug resistance. In addition, therapeutic strategies, including small-molecule inhibitors and small interfering RNA targeting histone demethylases to overcome drug resistance, are also described. Nature Publishing Group UK 2023-02-17 /pmc/articles/PMC9935618/ /pubmed/36797239 http://dx.doi.org/10.1038/s41392-023-01341-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Wang, Nan
Ma, Ting
Yu, Bin
Targeting epigenetic regulators to overcome drug resistance in cancers
title Targeting epigenetic regulators to overcome drug resistance in cancers
title_full Targeting epigenetic regulators to overcome drug resistance in cancers
title_fullStr Targeting epigenetic regulators to overcome drug resistance in cancers
title_full_unstemmed Targeting epigenetic regulators to overcome drug resistance in cancers
title_short Targeting epigenetic regulators to overcome drug resistance in cancers
title_sort targeting epigenetic regulators to overcome drug resistance in cancers
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935618/
https://www.ncbi.nlm.nih.gov/pubmed/36797239
http://dx.doi.org/10.1038/s41392-023-01341-7
work_keys_str_mv AT wangnan targetingepigeneticregulatorstoovercomedrugresistanceincancers
AT mating targetingepigeneticregulatorstoovercomedrugresistanceincancers
AT yubin targetingepigeneticregulatorstoovercomedrugresistanceincancers